Kenneth Galbraith's Net Worth
$735 Thousand
Who is Kenneth Galbraith?
Kenneth Galbraith does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Zymeworks Inc., MACROGENICS INC, Zymeworks Inc., and Celator Pharmaceuticals Inc.
SEC CIK
Kenneth Galbraith's CIK is 0001567045
Past Insider Trading and Trends
2020 was Kenneth Galbraith's most active year for acquiring shares with 3 total transactions. Kenneth Galbraith's most active month to acquire stocks was the month of April. 2020 was Kenneth Galbraith's most active year for disposing of shares, totalling 4 transactions. Kenneth Galbraith's most active month to dispose stocks was the month of August. 2020 saw Kenneth Galbraith paying a total of $361,102.60 for 35,773 shares, this is the most they've acquired in one year. In 2020 Kenneth Galbraith cashed out on 41,546 shares for a total of $563,156.03, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Zymeworks Inc. No price found
Chair, President & CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 15
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
MACROGENICS INC (MGNX) Snapshot price: $3.1701
InvestorKenneth Galbraith used to own units in Common Stock but no longer holds any shares there. In the year 2013 Kenneth Galbraith filed a total of 12 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 13
| |||
Form 4
|
—
|
0
|
$22.24 | -$202,053.43 |
0
|
Sep 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 5
| |||
Form 4
|
∞
| 1.32M |
$16.00 |
—
| 1.32M |
Oct 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 9
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Zymeworks Inc. (ZYME) Snapshot price: $11.56
Chair & CEOKenneth Galbraith owns 23,762 units of Common Stock which is worth $274,688.72. From 2022 to 2024 Kenneth Galbraith acquired a total of 47,666 shares in Zymeworks Inc., Kenneth also disposed a total of 23,904 shares of Zymeworks Inc. equalling to $257,844.95.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 23.76K |
$10.79 | -$257,844.95 | 23.76K |
Jan 5 - Jan 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 22
| |||
| No matching records found | |||||||||
Celator Pharmaceuticals Inc No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||